Pioneering Gyroscope Therapeutics Aims To Develop One-Time Gene Therapy For AMD

 
• By Sten Stovall

Gyroscope Therapeutics, which aims to develop genetically defined therapies for a range of eye diseases, has begun dosing in a Phase I/II clinical trial in dry age-related macular degeneration using its lead candidate.

Eye
Gyroscope Is Using Its GT005 Gene Therapy In An AMD Trial • Source: Shutterstock

More from Clinical Trials

More from R&D